CD274 and neoplasm: In preclinical syngeneic models of prostate cancer, a combination of radiotherapy (20 Gy in two fractions) with antibodies against programmed death-1 (anti-PD-1) or programmed death ligand-1 (anti-PD-L1) (iRT) significantly increased median survival (70–130%) in comparison to anti-PD-1 monotherapy, contributing to an abscopal response in which the unirradiated tumours responded similarly to the irradiated tumours.